Sigma Life Science CompoZr Knockout ZFN extended range

Sigma Life Science has announced a further development of its CompoZr zinc finger nuclease (ZFN) technology with the release of its Knockout ZFNs covering the entire genomes of both mice and rats. The expansion of the Knockout ZFNs for every mouse and rat gene is in its initial phase, which complements the existing range of Knockout ZFNs for the entire human genome.

ZFN technology has been recognised as the most efficient and versatile method of genetic engineering for cell lines and whole organisms, offering precisely targeted, permanent and heritable modifications in a fraction of the time required using more traditional technologies. ZFNs have been broadly adopted within the biotechnology and pharmaceutical sectors, and to address its high costs, the company has used new design and production processes to increase its affordability in an effort to help researchers accelerate scientific discovery. The new development and manufacturing facility is expected to ensure affordable pricing for Sigma’s complete range of CompoZr ZFN offerings and further extend the scope of this genome editing technology.